Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)


Monday 11 January, 2021

Sensyne Health PLC

Notice of Interim Results

RNS Number : 1561L
Sensyne Health PLC
11 January 2021




Notice of Interim Results


Oxford, UK; 11 January 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company") , the Clinical AI company, will announce its Interim Results for the 6 months ended 31 October 2020 on Thursday 21 January 2021.


Lord (Paul) Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will host a virtual briefing for analysts and investors at 13:00 GMT on the day of the results.


Details of the webcast, and the presentation slides, will be available via the Company website. For more details please contact [email protected]






For more information please contact:


Sensyne Health ( )

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer


Michael Norris, Interim Chief Financial Officer


Dr Richard Pye, Chief Investment Officer


Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

Dr Christopher Golden


James Steel


Oliver Jackson


Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma


Euan Brown


Consilium Strategic Communications

+44 (0) 7780600290

Mary-Jane Elliott


Sukaina Virji


Davide Salvi







About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).


For more information, please visit:



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t